Alebund Pharmaceuticals
Tracked across 1 events · 6 articles · First seen Jul 20, 2026 · Last active Sep 08, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Alebund Pharmaceuticals announced that the U.S. United States — Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for AP308, a first-in-class engineered recombinant IgA protease for the treatment of IgA nephropathy…
Impact: Alebund is the developer of AP308 and the primary beneficiary of the FDA IND clearance, which advances its pipeline and positively impacts its stock.
Jul 20, 2026 · 6 articles
100
United States — Food and Drug Administration cleared IND application Alebund PharmaceuticalsAlebund AP308 FDA IND Clearance
60
Alebund Pharmaceuticals entered license agreement Peking University First HospitalAlebund AP308 FDA IND Clearance
50
Alebund Pharmaceuticals published preclinical resultsAlebund AP308 FDA IND Clearance
ERGEN INTELLIGENCE
Track Alebund Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard